Amgen, Takeda suspend enrollment in a lung-cancer-drug study

TEL AVIV (MarketWatch) — Amgen Inc., the Thousand Oaks, Calif., biotech major, and Takeda Pharmaceutical Co.’s Millennium subsidiary suspended enrollment of patients in a Phase III trial of motesanib combined with paclitaxel and carboplatin as a first-line treatment for advanced non-small-cell lung cancer. Early-mortality rates in the motesanib group were higher than those in the placebo group, and the study’s data-monitoring committee urged the companies to temporarily halt enrolling patients in the 600-patient study, the companies said in a statement late on Wednesday.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Original post by Forextvblog

This entry was posted on Wednesday, November 19th, 2008 at 11:53 pm and is filed under Daily Forex Analysis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.